Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEROS CORPORATION

(OMER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Omeros Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021

08/09/2021 | 04:02pm EDT

Omeros Corporation announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 24.016 million compared to USD 27.680 million a year ago. Net loss was USD 28.593 million compared to USD 33.294 million a year ago. Basic loss per share from continuing operations was USD 0.46 compared to USD 0.61 a year ago. For the half year, operating loss was USD 54.628 million compared to USD 51.357 million a year ago. Net loss was USD 63.683 million compared to USD 62.325 million a year ago. Basic loss per share from continuing operations was USD 1.02 compared to USD 1.14 a year ago.


© S&P Capital IQ 2021
All news about OMEROS CORPORATION
10/19OMEROS : HC Wainwright Adjusts Price Target on Omeros to $12 From $19, Maintains Buy Ratin..
MT
10/18Top Midday Decliners
MT
10/18Omeros Shares Tumble as FDA Turns Away Narsoplimab Application
DJ
10/18Top Premarket Decliners
MT
10/18OMEROS : Receives Complete Response Letter from FDA for Biologics License Application for ..
PU
10/18OMEROS : Says FDA Requires Additional Information on Stem Cell Transplant Therapy Narsopli..
MT
10/18OMEROS CORP : Change in Directors or Principal Officers, Regulation FD Disclosure, Other E..
AQ
10/18Omeros Corporation Announces Retirement of Ray Aspiri from the Board of Directors
CI
10/18OMEROS : Receives Complete Response Letter from FDA for Biologics License Application for ..
BU
10/18Omeros Receives Complete Response Letter from FDA for Biologics License Application for..
CI
More news
Analyst Recommendations on OMEROS CORPORATION
More recommendations
Financials (USD)
Sales 2021 108 M - -
Net income 2021 -124 M - -
Net Debt 2021 334 M - -
P/E ratio 2021 -3,37x
Yield 2021 -
Capitalization 406 M 406 M -
EV / Sales 2021 6,84x
EV / Sales 2022 4,96x
Nbr of Employees 277
Free-Float 95,9%
Chart OMEROS CORPORATION
Duration : Period :
Omeros Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEROS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 6,49 $
Average target price 18,75 $
Spread / Average Target 189%
EPS Revisions
Managers and Directors
Gregory A. Demopulos Chairman, President & Chief Executive Officer
Michael A. Jacobsen Chief Financial Officer, Treasurer & VP
George A. Gaitanaris Chief Scientific Officer & Vice President-Science
J. Steven Whitaker Chief Medical Officer & Vice President
Thomas J. Cable Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OMEROS CORPORATION-54.57%406
CSL LIMITED4.48%100 729
WUXI BIOLOGICS (CAYMAN) INC.10.21%61 841
SAMSUNG BIOLOGICS CO.,LTD.6.54%49 427
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.8.14%39 464